Reported results
- GAAP research and development expenses were $12.5 million for the quarter ended September 30, 2026.
- GAAP selling, general and administrative expenses were $6.2 million for the quarter ended September 30, 2026.
- GAAP net loss was $14.2 million for the quarter ended September 30, 2026.
- Non-GAAP Adjusted EBITDA was negative $16.0 million for the quarter ended September 30, 2026.
- As of September 30, 2026, the company had $31.5 million in cash and cash equivalents.
Guidance
- Quarterly operating cash spending expected to be reduced to approximately $8 million by the end of Q2 2027.
- Cash runway into Q2 2027.
Notes
All share and per share information has been retroactively adjusted to reflect the 1-for-12 reverse stock split effected on October 2, 2026.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.
